<![CDATA[Novel Cancer Vaccine Meets Primary, Secondary End Points in Resected Melanoma]]>

Data ReadoutpositiveV0940pembrolizumabPositive

AI Analysis

Summary

V0940 in combination with pembrolizumab demonstrated statistically significant and clinically meaningful improvement in the INTERpath-001 trial for resected melanoma, meeting both primary and secondary endpoints.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

INTERpath-001 trial met primary and secondary endpoints with statistically significant and clinically meaningful improvement

Importance:7/10

Sentiment:

0.75

melanomacancer vaccineimmunotherapyclinical trial

Related Companies

$MRK

Read the original article

Published by Cancer Network on August 19, 2026 1:31 PM

Read Original